Department of Ophthalmology, Ministry of Education Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, TaiKang Center for Life and Medical Sciences, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan, 430071, China.
College of Biomedical Engineering, Sichuan University, Chengdu, 610065, China.
Adv Mater. 2024 Sep;36(38):e2407268. doi: 10.1002/adma.202407268. Epub 2024 Aug 1.
Clinical multidrug-resistant Pseudomonas aeruginosa (MDR-PA) is the leading cause of refractory bacterial keratitis (BK). However, the reported BK treatment methods lack biosecurity and bioavailability, which usually causes irreversible visual impairment and even blindness. Herein, for BK caused by clinically isolated MDR-PA infection, armed phages are modularized with the type I photosensitizer (PS) ACR-DMT, and an intelligent phage eyedrop is developed for combined phagotherapy and photodynamic therapy (PDT). These eyedrops maximize the advantages of bacteriophages and ACR-DMT, enabling more robust and specific targeting killing of MDR-PA under low oxygen-dependence, penetrating and disrupting biofilms, and efficiently preventing biofilm reformation. Altering the biofilm and immune microenvironments alleviates inflammation noninvasively, promotes corneal healing without scar formation, protects ocular tissues, restores visual function, and prevents long-term discomfort and pain. This strategy exhibits strong scalability, enables at-home treatment of ocular surface infections with great patient compliance and a favorable prognosis, and has significant potential for clinical application.
临床多重耐药铜绿假单胞菌(MDR-PA)是难治性细菌性角膜炎(BK)的主要原因。然而,报道的 BK 治疗方法缺乏生物安全性和生物利用度,通常会导致不可逆转的视力损害,甚至失明。在此,对于由临床分离的 MDR-PA 感染引起的 BK,武装噬菌体与 I 型光敏剂(PS) ACR-DMT 模块化,并开发了智能噬菌体滴眼剂以进行联合噬菌体治疗和光动力治疗(PDT)。这些滴眼剂最大限度地发挥了噬菌体和 ACR-DMT 的优势,使 MDR-PA 在低氧依赖性下更加强劲和特异性靶向杀伤,穿透和破坏生物膜,并有效地防止生物膜再形成。改变生物膜和免疫微环境可无创缓解炎症,促进角膜愈合而无瘢痕形成,保护眼组织,恢复视觉功能,并防止长期不适和疼痛。该策略具有很强的可扩展性,可实现家庭治疗眼部表面感染,患者顺应性好,预后良好,具有重要的临床应用潜力。